Enhanced expression of CD74 in gastrointestinal cancers and benign tissues

International Journal of Clinical and Experimental Pathology

Volumn 4, Issue 1, 2011, Pages 1-12

  Gold, David V ^a   Stein, Rhona ^a   Burton, Jack ^a   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Cd74; Colon carcinoma; Gastric carcinoma; Invariant chain; Pancreatic carcinoma

Indexed keywords

B LYMPHOCYTE ANTIGEN; HLA ANTIGEN CLASS 2; TUMOR MARKER;

ADENOCARCINOMA; ADENOMA; ARTICLE; COLORECTAL TUMOR; DIGESTIVE SYSTEM TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; INVARIANT CHAIN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; STOMACH TUMOR; TISSUE MICROARRAY;

ADENOCARCINOMA; ADENOMA; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; COLORECTAL NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREATIC NEOPLASMS; STOMACH NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79955095068     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Claesson L, Larhammer D, Rask L, Peterson PA. cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure. Proc Natl Acad Sci USA 1983;80:7395-9.
2. Roche PA, Cresswell P. Intracellular transport of class II MHC molecules directed by invarient chain. Nature 1990;345:615-18.
3. Roche PA, Teletski CL, Stang E, Bakke O, Long EO. Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA, 1993;90:8581-5.
4. Moller P, Henne C, Moldenhauer G. CD74 Workshop Panel Report. In: Schlossman SF, Boumsell L, Gilks W, et al. (eds.), Leukocyte Typing V, White cell differentiation Antigens, Vol 1. Oxford University Press: New York; 1995. pp. 568-571.
5. Hansen HJ, Ong GL, Diril H, Valdez A, Roche PA, Griffiths GL, Goldenberg DM, Mattes MJ. Internalization and catabolism of radiolabeled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300.
6. Ong GL, Goldenberg DM, Hansen HJ, Mattes MJ. Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 1999;98:296-302.
7. Leng L, Metz CN, Fang Y, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
8. Shi X, Leng L, Wang T, Wang W, Du X, Li J, McDonald C, Chen Z, Murphy JW, Lolis E, Noble P, Knudson W, Bucala R. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 2006;25:595-606.
9. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S, Berrebi A, Shachar I. Cell surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107:4807-16.
10. Beswick EJ, Das S, Pinchuk IV, Adegboyega P, Suarez G, Yamaoka Y, Reyes VE. Helicobactor pylori-induced IL-8 production by gastric epithelial cells up-regulates CD74 expression. J Immunol 2005;175:171-6.
11. Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM. CD74 is expressed by multiple myeloma cells and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11.
12. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, Hansen HJ, Goldenberg DM. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104:3705-11.
13. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Iwashige H, Aridome K, Hokita S, Aikou T. Invariant chain expression in gastric cancer. Cancer Lett 2001;168:87-91.
14. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA. Differential CD74 (major histocompatiability complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer 2009;145:318-32.
15. Hustinx SR, Cao, D, Maitra A, Sato N, Martin ST, Sudhir D, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Kern SE, Goggins M, Mollenhauer J, Pandey A, Hruban RH. Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biol Therapy 2004;3:1254-61.
16. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2002;158:1639-51.
17. Ioachim HL, Pambuccian SE, Hekimgil M, Giancotti FR, Dorsett BH. Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am J Surg Pathol 1996;20:64-71.
18. Kitange GJ, Carlson BL, Schroeder MA, Decker PA, Morlan BW, Wu W, Ballman KV, Giannini C, Sarkaria JN. Expression of CD74 in high grade gliomas: a potential role in temozolomide resistance. J Neurooncol. 2010 May 5. [Epub ahead of print]
19. Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ. Class IIassociated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 2004;64:5546-50.
20. Koide N, Yamada T, Shibata R, Mori T, Fukuma M, Yamazaki K, Aiura K, Shimazu M, Hirohashi S, Nimura Y, Sakamoto M. Establishment of perineural invasion models and analysis of gene expression revealed an invariant chain (CD74) as a possible molecule involved in perineural invasion in pancreatic cancer. Clin Cancer Res 2006;12:2419-26.
21. Pawlak-Byczkowska EJ, Hansen HJ, Dion AS, Goldenberg DM. Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma. Cancer Res 1989;49:4568-77.
22. Gold DV, Karanjawala Z, Modrak DE, Goldenberg DM, Hruban RH. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin Cancer Res 2007;13:7380-7.
23. Maharshak N, Cohen S, Lantner F, Hart G, Leng L, Bucala R, Shachar I. CD74 is a survival receptor on colon epithelial cells. World J Gastroenterol 2010;16:3258-66.
24. Beswick EJ, Pinchuk IV, Suarez G, Sierra JC and Reyes VE. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol 2006;176:6794-801.
25. Hruban RH, Maitra A, and Goggins, M. Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol 2008;1:306-16.
26. Morris, P, Shaman J, Attaya M, Amaya M, Goodman S, Bergman C, Monaco JJ, Mellins E. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules. Nature 1994;368:551.
27. Hillman GG, Kallinteris NL, Li J, Wang Y, Lu X, Li Y, Wu S, Wright JL, Slos P, Gulfo JV, Humphreys RE, Xu M. Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells. Gene Ther 2003;10:1512-8.
28. Lu X, Kallinteris NL, Li J, Wu S, Li Y, Jiang Z, Hillman GG, Gulfo JV, Humphreys RE, Xu M. Tumor immunotherapy by converting tumor cells to MHC class II-positive, Ii protein-negative phenotype. Cancer Immunol Immunother 2003;52:592-8.
29. Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM. CD74: A new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s.
30. Xu M, Li J, Gulfo JV, Von Hofe E, Humphreys RE. MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases. Scand J Immunol 2001;54:39-44.
31. Stein R, Smith MR, Chen S, Zalath M, Goldenberg DM. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma. Clin Cancer Res 2007;15:2808-17.
32. Kaufman JL, Niesvizky R, Stadtmauer EA, Chanan-Khan A, Siegel D, Horne H, Teoh N, Wegener WA, Goldenberg DM. Dose-escalation trial of milatuzumab (humanized anti-CD74 monoclonal antibody) in multiple myeloma [abstract]. J Clin Oncol 2009;27:15s.
33. Jiang Z, Xu M, Savas L, LeClair P, Banner BF. Invariant chain expression in colon neoplasms. Virchows Arch 1999;435:32-6.
34. Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15:2855-61.
35. Barrera CA, Beswick EJ, Sierra JC, Bland D, Espejo R, Mifflin R, Adegboyega P, Crowe SE, Ernst PB, Reyes VE. Polarized expression of CD74 by gastric epithelial cells. J Histochem Cytochem 2005;53:1481-9.
36. Beswick EJ, Reyes VE. Macrophage migration inhibitory factor and interleukin-8 produced by gastric epithelial cells during Helicobacter pylori exposure induce expression and activation of epidermal growth factor receptor. Infect Immun 2008;76:3233-40.
37. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008;283:2784-92.
38. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S. Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol 1992;149:2391-96.
39. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-91.